Osteoporosis and vertebral fractures in ankylosing spondylitis

Nicole Davey-Ranasinghe, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To review the recent literature on the prevalence of osteoporosis, risk of vertebral fractures, and the recent advances in the treatment of osteoporosis in patients with ankylosing spondylitis (AS). RECENT FINDINGS: Newer data suggest that the prevalence of osteoporosis is 25% and vertebral fractures is 10% in patients with AS. New advances in the field of osteoimmunology help explain the trabecular bone loss and generalized osteoporosis linked to increased expression of receptor activator of nuclear factor kappa B ligand (RANK-L) due to pro-inflammatory cytokines, and the simultaneous new bone formation (e.g. syndesmophytes) in areas of previous inflammation through suppressed Dickkopf-related protein 1 levels and increased WNT (wingless) signaling. SUMMARY: Osteoporosis is a common problem for patients with AS. We recommend screening within 10 years of diagnosis. Suspecting and promptly recognizing vertebral fractures in patients with AS could prevent serious neurological complications. Although bisphosphonates and tumor necrosis factor-α inhibitors look promising, further prospective trials on the treatment of osteoporosis in AS are needed.

Original languageEnglish (US)
Pages (from-to)509-516
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume25
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Ankylosing Spondylitis
Osteoporosis
RANK Ligand
Diphosphonates
Osteogenesis
Tumor Necrosis Factor-alpha
Cytokines
Inflammation
Therapeutics
Proteins

Keywords

  • ankylosing spondylitis
  • osteoimmunology
  • osteoporosis
  • vertebral fractures

ASJC Scopus subject areas

  • Rheumatology

Cite this

Osteoporosis and vertebral fractures in ankylosing spondylitis. / Davey-Ranasinghe, Nicole; Deodhar, Atulya (Atul).

In: Current Opinion in Rheumatology, Vol. 25, No. 4, 07.2013, p. 509-516.

Research output: Contribution to journalArticle

@article{cc59e95d10b4451dbf8bbd140a0ba8a3,
title = "Osteoporosis and vertebral fractures in ankylosing spondylitis",
abstract = "PURPOSE OF REVIEW: To review the recent literature on the prevalence of osteoporosis, risk of vertebral fractures, and the recent advances in the treatment of osteoporosis in patients with ankylosing spondylitis (AS). RECENT FINDINGS: Newer data suggest that the prevalence of osteoporosis is 25{\%} and vertebral fractures is 10{\%} in patients with AS. New advances in the field of osteoimmunology help explain the trabecular bone loss and generalized osteoporosis linked to increased expression of receptor activator of nuclear factor kappa B ligand (RANK-L) due to pro-inflammatory cytokines, and the simultaneous new bone formation (e.g. syndesmophytes) in areas of previous inflammation through suppressed Dickkopf-related protein 1 levels and increased WNT (wingless) signaling. SUMMARY: Osteoporosis is a common problem for patients with AS. We recommend screening within 10 years of diagnosis. Suspecting and promptly recognizing vertebral fractures in patients with AS could prevent serious neurological complications. Although bisphosphonates and tumor necrosis factor-α inhibitors look promising, further prospective trials on the treatment of osteoporosis in AS are needed.",
keywords = "ankylosing spondylitis, osteoimmunology, osteoporosis, vertebral fractures",
author = "Nicole Davey-Ranasinghe and Deodhar, {Atulya (Atul)}",
year = "2013",
month = "7",
doi = "10.1097/BOR.0b013e3283620777",
language = "English (US)",
volume = "25",
pages = "509--516",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Osteoporosis and vertebral fractures in ankylosing spondylitis

AU - Davey-Ranasinghe, Nicole

AU - Deodhar, Atulya (Atul)

PY - 2013/7

Y1 - 2013/7

N2 - PURPOSE OF REVIEW: To review the recent literature on the prevalence of osteoporosis, risk of vertebral fractures, and the recent advances in the treatment of osteoporosis in patients with ankylosing spondylitis (AS). RECENT FINDINGS: Newer data suggest that the prevalence of osteoporosis is 25% and vertebral fractures is 10% in patients with AS. New advances in the field of osteoimmunology help explain the trabecular bone loss and generalized osteoporosis linked to increased expression of receptor activator of nuclear factor kappa B ligand (RANK-L) due to pro-inflammatory cytokines, and the simultaneous new bone formation (e.g. syndesmophytes) in areas of previous inflammation through suppressed Dickkopf-related protein 1 levels and increased WNT (wingless) signaling. SUMMARY: Osteoporosis is a common problem for patients with AS. We recommend screening within 10 years of diagnosis. Suspecting and promptly recognizing vertebral fractures in patients with AS could prevent serious neurological complications. Although bisphosphonates and tumor necrosis factor-α inhibitors look promising, further prospective trials on the treatment of osteoporosis in AS are needed.

AB - PURPOSE OF REVIEW: To review the recent literature on the prevalence of osteoporosis, risk of vertebral fractures, and the recent advances in the treatment of osteoporosis in patients with ankylosing spondylitis (AS). RECENT FINDINGS: Newer data suggest that the prevalence of osteoporosis is 25% and vertebral fractures is 10% in patients with AS. New advances in the field of osteoimmunology help explain the trabecular bone loss and generalized osteoporosis linked to increased expression of receptor activator of nuclear factor kappa B ligand (RANK-L) due to pro-inflammatory cytokines, and the simultaneous new bone formation (e.g. syndesmophytes) in areas of previous inflammation through suppressed Dickkopf-related protein 1 levels and increased WNT (wingless) signaling. SUMMARY: Osteoporosis is a common problem for patients with AS. We recommend screening within 10 years of diagnosis. Suspecting and promptly recognizing vertebral fractures in patients with AS could prevent serious neurological complications. Although bisphosphonates and tumor necrosis factor-α inhibitors look promising, further prospective trials on the treatment of osteoporosis in AS are needed.

KW - ankylosing spondylitis

KW - osteoimmunology

KW - osteoporosis

KW - vertebral fractures

UR - http://www.scopus.com/inward/record.url?scp=84879885595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879885595&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e3283620777

DO - 10.1097/BOR.0b013e3283620777

M3 - Article

C2 - 23719363

AN - SCOPUS:84879885595

VL - 25

SP - 509

EP - 516

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 4

ER -